Cisplatin-etoposide versus paclitaxel-carboplatin along with thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer: a comparison of treatment response

Janak Raman Parajuli; Tasnim Tabassum; Mostafa Sanaul Haque; Shourov Biswas; M. Masudur Rahman; Prakriti Siwakoti; Jayantta Chakraborty

doi:10.18203/2320-6012.ijrms20243352

Authors

Janak Raman Parajuli Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Tasnim Tabassum Ahsania Mission Cancer and General Hospital, Dhaka, Bangladesh
Mostafa Sanaul Haque Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Shourov Biswas Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
M. Masudur Rahman Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh https://orcid.org/0000-0002-2986-0798
Prakriti Siwakoti Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Jayantta Chakraborty Ministry of Health and Family Welfare, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20243352

Keywords:

Non-small cell lung cancer, Lung cancer, Locally advanced, Concurrent chemoradiation, Carboplatin and paclitaxel, Cisplatin and etoposide

Abstract

Background: Although many chemotherapy regimens are used concurrently with radiotherapy in locally advanced non-small cell lung cancer (NSCLC), the ideal chemotherapy regimen is yet to be determined. The purpose of this study was to compare the therapeutic response of cisplatin-etoposide (EP) and paclitaxel-carboplatin (PC) combined with thoracic radiation in unresectable locally advanced NSCLC.

Methods: A quasi-experimental study was conducted from October 2020 to September 2021 at two centers in Dhaka. Patients with unresectable, locally advanced, histology proven NSCLC were enrolled and distributed equally in two arms. Patients underwent 60 Gy in 2 Gy daily fractions, five days/week, for six weeks of thoracic radiotherapy with either cisplatin 50 mg/m² and etoposide 50 mg/m²/day (arm A), or carboplatin (AUC-2) and paclitaxel (45 mg/m²) (arm B). All the patients were evaluated before, during, and after the completion of the treatment. Follow ups were done at 6 weeks, 12 weeks and 24 weeks following the completion of treatment.

Results: Seventy-four patients were distributed equally into two arms. After 6 weeks 3 (8.11%) patients had complete response (CR), 28 (75.68%) had partial response (PR), and 6 (16.22%) had stable disease (SD) in arm-A. In arm-B, 1 (2.71%), 24 (64.86%), 12 (32.43%) patients had CR, PR and SD respectively. In either arm none had progressive disease (PD). After 24 weeks, 5 (13.51%) versus 2 (5.41%) patients had CR, 15 (40.54%) versus 16 (43.24%) had SD, and 4 (10.81%) versus 6 (16.21%) had PD in arm-A and arm-B respectively. PR was 13 (35.14%) in both arms. But these differences were not significant (p>0.05).

Conclusions: In unresectable locally advanced non-small cell lung cancer, the short-term treatment response of a cisplatin-etoposide regimen given with concurrent radiation therapy is comparable to that of a paclitaxel-carboplatin regimen.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

National Institute of Cancer Research and Hospital. Hospital Cancer Registry Report 2015-2017. Dhaka; 2020.

Warner KE, Mendez D. Tobacco control policy in developed countries: yesterday, today, and tomorrow. Nicotine Tobacco Res. 2010;12(9):876-87.

Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J. 2016;48(3):889-902.

Trichopoulos D, Lagiou P, Trichopoulou, A. Evidence-based nutrition. Asia Pac J Clin Nutr. 2000;9(Suppl.):S4-9.

Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Serum α-tocopherol and subsequent risk of lung cancer among male smokers. J Nat Cancer Inst. 1999;91(20):1738-43.

Curran Jr WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential versus concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Nat Cancer Inst. 2011;103(19):1452-60.

Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181-90.

Bezjak A, Temin S, Franklin G, Giaccone G, Govindan R, Johnson ML, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2015;33(18):2100-5.

Sause W, Kolesar P, Taylor IV S, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117(2):358-64.

Halperin EC, Wazer DE, Perez CA, Brady LW. Perez and Brady’s principles and practice of radiation oncology. 7th edn. Wolters Kluwer; 2019.

Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17(9):2692.

Bradley JD, Paulus R, Komaki R, Masters GA, Forster K, Schild SE, et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(15_suppl):7501.

Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT- A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192(4):216.

Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777-83.

Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, et al. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage iii non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017;3(8):1120-9.

Chu E, DeVita Jr VT. Physicians’ cancer chemotherapy drug manual 2020. Jones and Bartlett Learning; 2019.

Dobbs J, Barrett A, Morris S, Roques T. Practical radiotherapy planning. 4th edn. Hodder Arnold; 2009.

Bi N, Liu L, Liang J, Wu S, Chen M, Lv C, et al. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. BMC Cancer. 2020;20:1-10.

Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953-62.